Abstract：Objective To investigate the prognostic factors for survival in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma who received radical radiotherapy for primary tumors. Methods From 2008 to 2011,39 patients with newly diagnosed oligometastatic nasopharyngeal carcinoma received 1-6 cycles of chemotherapy and radical radiotherapy for primary tumors. In those patients,10 received conventional radiotherapy and 26 received intensity-modulated radiotherapy. The Kaplan-Meier method was used to calculate survival rates. The log-rank test and Cox model were used for univariate and multivariate prognostic analyses,respectively. Results The median follow-up time was 38 months. The 1-,2-,and 3-year overall survival rates were 97%,87%,and 70%,respectively,while the 1-,2-,and 3-year progression-free survival rates were 87%,65%,and 59%,respectively. Age,number of metastatic lesions,scheme of induction chemotherapy,and use of concurrent chemotherapy or not were independent prognostic factors for survival. The patients with no more than 3 metastatic lesions had a higher survival rate than those with more than 3 metastatic lesions (P=0.023).The patients undergoing chemotherapy with docetaxel had a significantly higher survival rate than those undergoing chemotherapy without docetaxel (P=0.041). Conclusions Induction chemotherapy and radical radiotherapy for primary tumors can still achieve long-term survival in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma,particularly in young patients with no more than 3 metastatic lesions. Compared with chemotherapy without docetaxel,chemotherapy with docetaxel may provide a greater survival benefit for patients.
Huang Shuang,Chen Yuanyuan,Jiang Feng et al. Efficacy of radical radiotherapy for primary tumors in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(1): 35-39.
[1] Ferlay J,Soerjomataram I,Dikshit R,et al. Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-E386.DOI:10.1002/ijc.29210 [2] Chan OSH,Ngan RKC.Individualized treatment in stage ⅠVC nasopharyngeal carcinoma[J].Oral Oncol,2014,50(9):791-797.DOI:10.1016/j.oraloncology.2014.01.004 [3] Hellman S,Weichselbaum RR.Oligometastases[J].J Clin Oncol,1995,13(1):8-10.DOI:10.1200/JCO.1995.13.1.8 [4] Fong Y,Fortner J,Sun RL,et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer:analysis of 1001 consecutive cases[J].Ann Surg,1999,230(3):309-318;discussion 318-21.DOI:10.1097/00000658-199909000-00004 [5] Pastorino U,Buyse M,Friedel G,et al. Long-term results of lung metastasectomy:prognostic analyses based on 5206 cases[J].J Thorac Cardiovasc Surg,1997,113(1):37-49.DOI:10.1016/S0022-5223(97)70397-0 [6] Setton J,Wolden S,Caria N,et al. Definitive treatment of metastatic nasopharyngeal carcinoma:report of 5 cases with review of literature[J].Head Neck,2012,34(5):753-757.DOI:10.1002/hed.21608 [7] 王春兰,苏胜发,欧阳伟炜,等.器官和病灶联合定义寡转移Ⅳ期NSCLC原发灶三维根治剂量放疗的意义——PPRA-RTOG 003再分析[J].中华放射肿瘤学杂志,2016,25(6):576-581.DOI:10.3760/cma.j.issn.1004-4221.2016.06.007.Wang CL,Su SF,Ouyang WW,et al. Significance of three-dimensional radical radiotherapy dose determined by organ-lesion combination for primary tumor of oligometastatic stage Ⅳ NSCLC:a reanalysis of PPRA-RTOG 003[J].Chin J Radiat Oncol,2016,25(6):576-581.DOI:10.3760/cma.j.issn.1004-4221.2016.06.007 [8] 蓝玉宏,田允铭,白力,等.初治转移鼻咽癌疗后预后评分模型建立及分层治疗研究[J].中华放射肿瘤学杂志,2015,24(4):421-426.DOI:10.3760/j.issn.1004-4221.2015.04.023.Lan YH,Tian YM,Bai L,et al. Post-treatment prognostic score model establishment and stratified therapy for newly diagnosed metastatic nasopharyngeal carcinoma[J].Chin J Radiatn Oncol,2015,24(4):421-426.DOI:10.3760/j.issn.1004-4221.2015.04.023 [9] Pan CC,He N,Zhao M,et al. Subdividing the M1 stage of liver metastasis for nasopharyngeal carcinoma to better predict metastatic survival[J].Med Oncol,2011,28(4):1349-1355.DOI:10.1007/s12032-010-9643-8 [10] 田允铭,韩非,曾雷,等.寡转移状态下初治鼻咽癌的预后及治疗模式探讨[J].中华放射肿瘤学杂志,2016,25(11):1156-1160.DOI:10.3760/cma.j.issn.1004-4221.2016.11.003.Tian YM,Han F,Zeng L,et al. Prognosis and treatment of newly diagnosed nasopharyngeal carcinoma with oligometastases[J].Chin J Radiat Oncol,2016,25(11):1156-1160.DOI:10.3760/cma.j.issn.1004-4221.2016.11.003 [11] Li W,Bai YT,Wu M,et al. Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver:propensity score matching analysis[J].Oncotarget,2017,8(32):52132-52141 [12] Tian YH,Zou WH,Xiao WW,et al. Oligometastases in AJCC stage ⅠVc nasopharyngeal carcinoma:a subset with better overall survival[J].Head Neck,2016,38(8):1152-1157.DOI:10.1002/hed.24345 [13] 郭晔.转移性鼻咽癌的系统性治疗[J].中国癌症杂志,2011,12(12):927-931.DOI:10.3969/j.issn.1007-3969.2011.12.005.Guo Y.Systemic treatment in metastatic nasopharyngeal carcinoma[J].China Oncol,2011,12(12):927-931.DOI:10.3969/j.issn.1007-3969.2011.12.005 [14] Zhang L,Huang Y,Hong SD,et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma:a multicentre,randomised,open-label,phase 3 trial[J].Lancet,2016,388(10054):1883-1892.DOI:10.1016/S0140-6736(16)31388-5 [15] Chua DTT,Sham JST,Au GKH.A phase Ⅱ study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma[J].Oral Oncol,2005,41(6):589-595.DOI:10.1016/j.oraloncology.2005.01.008 [16] Peng PJ,Lv BJ,Tang C,et al. Phase Ⅱ trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma[J].Drug Des Devel Ther,2015,9:6401-6405.DOI:10.2147/DDDT.S95946 [17] Tosoian JJ,Gorin MA,Ross AE,et al. Oligometastatic prostate cancer:definitions,clinical outcomes,and treatment considerations[J].Nat Rev Urol,2017,14(1):15-25.DOI:10.1038/nrurol.2016.175 [18] Golden EB,Chhabra A,Chachoua A,et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours:a proof-of-principle trial[J].Lancet Oncol,2015,16(7):795-803.DOI:10.1016/S1470-2045(15)00054-6 [19] Lin S,Tham IW,Pan J,et al. Combined high-dose radiation therapy and systemic chemotherapy improves survival in patients with newly diagnosed metastatic nasopharyngeal cancer[J].Am J Clin Oncol,2012,35(5):474-479.DOI:10.1097/COC.0b013e31821a9452 [20] Rusthoven CG,Lanning RM,Jones BL,et al. Metastatic nasopharyngeal carcinoma:patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy[J].Radiother Oncol,2017,124(1):139-146.DOI:10.1016/j.radonc.2017.03.019 [21] Setton J,Han J,Kannarunimit D,et al. Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma[J].Oral Oncol,2016,53:67-73.DOI:10.1016/j.oraloncology.2015.11.015 [22] Ou XM,Zhou X,Shi Q,et al. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy:new insight into the value of total dose of cisplatin and radiation boost[J].Oncotarget,2015,6(35):38381-38397.DOI:10.18632/oncotarget.5420 [23] Pan CC,Wu PH,Yu JR,et al. CT-guided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma[J].Int J Hyperthermia,2011,27(6):549-554.DOI:10.3109/02656736.2011.593019
2018, Vol. 27 
